Wall Street Zen Upgrades Microbot Medical (NASDAQ:MBOT) to Hold

Microbot Medical (NASDAQ:MBOT) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.

MBOT has been the subject of a number of other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Microbot Medical in a report on Saturday, September 27th. Zacks Research lowered shares of Microbot Medical from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 21st. Finally, HC Wainwright increased their price objective on shares of Microbot Medical from $9.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, September 11th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Microbot Medical currently has a consensus rating of “Hold” and a consensus price target of $12.00.

Microbot Medical Trading Down 3.2%

NASDAQ MBOT opened at $3.07 on Friday. Microbot Medical has a 12 month low of $0.88 and a 12 month high of $4.67. The stock has a market cap of $162.07 million, a price-to-earnings ratio of -5.29 and a beta of 1.25. The company’s 50 day moving average is $3.33 and its two-hundred day moving average is $2.69.

Microbot Medical (NASDAQ:MBOT) last announced its quarterly earnings data on Tuesday, August 12th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). Sell-side analysts forecast that Microbot Medical will post -0.71 EPS for the current year.

Institutional Trading of Microbot Medical

Several institutional investors and hedge funds have recently made changes to their positions in MBOT. Geode Capital Management LLC lifted its position in shares of Microbot Medical by 24.7% during the second quarter. Geode Capital Management LLC now owns 395,039 shares of the biotechnology company’s stock worth $996,000 after purchasing an additional 78,121 shares during the last quarter. DNB Asset Management AS lifted its position in shares of Microbot Medical by 67.9% during the second quarter. DNB Asset Management AS now owns 192,786 shares of the biotechnology company’s stock worth $486,000 after purchasing an additional 77,965 shares during the last quarter. Goldman Sachs Group Inc. bought a new stake in shares of Microbot Medical during the first quarter worth $57,000. Virtu Financial LLC bought a new stake in shares of Microbot Medical during the first quarter worth $42,000. Finally, Lazari Capital Management Inc. bought a new stake in shares of Microbot Medical during the second quarter worth $54,000. 16.30% of the stock is currently owned by institutional investors.

About Microbot Medical

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.